Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of “Hold” from Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has been assigned a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $18.63.

Several research firms have weighed in on CYRX. Stephens reiterated an “equal weight” rating and issued a $17.00 target price on shares of Cryoport in a report on Wednesday, March 13th. Needham & Company LLC cut their target price on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. UBS Group increased their target price on shares of Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a report on Friday, March 15th. Finally, Jefferies Financial Group began coverage on shares of Cryoport in a report on Thursday. They issued a “buy” rating and a $21.00 target price on the stock.

Cryoport Trading Down 1.9 %

Shares of NASDAQ CYRX opened at $18.21 on Tuesday. The company’s 50 day simple moving average is $16.41 and its 200 day simple moving average is $14.56. Cryoport has a fifty-two week low of $9.00 and a fifty-two week high of $24.17. The firm has a market capitalization of $895.20 million, a P/E ratio of -8.28 and a beta of 1.60. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.19). Cryoport had a negative net margin of 42.69% and a negative return on equity of 11.86%. The business had revenue of $57.26 million during the quarter, compared to analyst estimates of $58.27 million. On average, analysts predict that Cryoport will post -1.29 EPS for the current year.

Insider Buying and Selling at Cryoport

In other news, CEO Jerrell Shelton sold 57,039 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $15.30, for a total transaction of $872,696.70. Following the transaction, the chief executive officer now directly owns 634,352 shares in the company, valued at approximately $9,705,585.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Ramkumar Mandalam sold 3,217 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now directly owns 43,187 shares in the company, valued at approximately $633,985.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 57,039 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $15.30, for a total transaction of $872,696.70. Following the transaction, the chief executive officer now owns 634,352 shares in the company, valued at $9,705,585.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,940 shares of company stock worth $1,147,538. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in shares of Cryoport by 228.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock worth $36,000 after purchasing an additional 1,433 shares during the last quarter. Quarry LP bought a new stake in shares of Cryoport during the 2nd quarter worth about $40,000. Captrust Financial Advisors boosted its holdings in shares of Cryoport by 308.3% during the 2nd quarter. Captrust Financial Advisors now owns 2,319 shares of the company’s stock worth $72,000 after buying an additional 1,751 shares during the period. FMR LLC boosted its holdings in shares of Cryoport by 34.1% during the 1st quarter. FMR LLC now owns 2,935 shares of the company’s stock worth $70,000 after buying an additional 747 shares during the period. Finally, State of Wyoming boosted its holdings in shares of Cryoport by 42.7% during the 4th quarter. State of Wyoming now owns 3,026 shares of the company’s stock worth $53,000 after buying an additional 905 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.